Herein, we present the identification and characterization of eltrombopag as a METTL3-14 allosteric inhibitor, including the prediction of a putative binding site, anti-proliferative effects on AML cell lines, and an analysis of the influences on the m6A abundance on a cellular level. Here, METTL3 is linked to acute myeloid leukemia.